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ABSTRACT
Background: Knee osteoarthritis is one of the most prevalent chronic disorders. Several pharmacological and non pharmacological 
approaches are used to treat this disease. Today, the effect of B and E vitamins on rheumatology diseases is being discussed. In this study, 
the efficacy of B and E vitamins accompanied with diclofenac on pain relief in patients with knee osteoarthritis was investigated and com-
pared. Methods: In this double-blinded clinical trial, 120 patients with knee osteoarthritis referring training Rheumatology and Ortho-
pedics Clinic of Shahrekord University of Medical sciences were investigated. Of these patients, 12 were excluded throughout the study. 
The patients underwent treatment in three groups (oral diclofenac + oral B vitamin, oral diclofenac + oral vitamin E, and oral diclofenac + 
placebo). Pain relief was assessed by visual analogue scale (VAS) questionnaire and morning stiffness and physical function were assessed 
by WOMAC standard questionnaire at three times; the first examination, two weeks, and three weeks after referring. Results: The mean 
score of WOMAC questionnaire at VASs of knee pain, total pain severity, knee joint stiffness, and function of the last 48 hours decreased 
significantly in all three groups (diclofenac, E and B vitamins) from the first to third examination (P<0.001). Decrease in VAS of knee pain 
and function of the last 48 hours was higher in B vitamin group than the diclofenac and E vitamin group (P=0.008) and decrease in total 
pain severity was reported higher in B vitamin group than E vitamin and diclofenac group (P=0.019). Decrease in knee joint stiffness 
underwent a similar trend in the three groups. Conclusion: In view similar analgesic and anti-inflammatory properties, as well as very 
few, non prevalent complications of B and E vitamins, use of two or more drugs with a different mechanism of effect seems necessary to 
enhance their effect on osteoarthritis treatment.
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1. INTRODUCTION
Osteoarthritis or arthrosis is one of the most prevalent 
types of arthritis and chronic joint disorder in human, 
which could lead to severe pain and chronic disability 
particularly in hip and knee (1-3). Studies have indicated 
that approximately 1/3 of above 45-year-old population of 
the USA suffer from osteoarthritis and it will become the 
fourth reason for increased worldwide due to increased 
life expectancy, sedentary lifestyle, and increased obesity 
rate (4, 5). In Iran, the prevalence of knee osteoarthritis 
in the ages over 15 years old was reported approximate-
ly 15.34%, which is considered a high prevalence (6). The 
treatment of this disease includes relieving pain and deal-
ing with lack of physical function by means of multi-fac-
eted, non pharmacological approaches. Today, the most 
commonly used drugs for pain relief in these patients are 
nonsteroidal anti-inflammatory drugs (NSAIDs) such as 
diclofenac. Diclofenac is an analgesic, anti-inflammatory 
drug and one of the most efficient inhibitors of prosta-
glandins which is used in treatment of rheumatic diseases 
(7, 8). Diclofenac could lead to headache, dizziness, rash, 
edema, and kidney and liver damage. The complications 
caused by this drug restrict its clinical usage (9, 10). To-
day, various supplements are used for osteoarthritis treat-
ment. B vitamins are water-soluble vitamins, have been 
used as analgesic drug and promoter of analgesic effect of 
diclofenac in many studies, and cause a decrease in dura-
tion of treatment (11-13). Vitamin B complex (thiamine 
[B1], niacin [B3], cobalamin [B12]) is used not only for 
treatment of pain and inflammation but also, alone or ac-
companied with diclofenac, for various diseases such as 
polyneuropathy, spinal degenerative disease, rheumatic 
diseases and the pain following tonsillectomy (9,14). Me-
dina-Santillan et al study indicated that consumption of 
diclofenac decreased by 30% in the patients who received 
vitamin B complex (7). B vitamin is one of the lipid-solu-
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ble vitamins in cell membrane. This vitamin neutralizes 
hydrogen peroxide and protects cell membrane against 
peroxidation (15). Alpha-tocopherol is a form of E vita-
min which has the highest biological activity and its most 
abundant form exists in the body. Although all tocoph-
erol homologues are absorbed similarly, alpha form is 
mainly found in blood and tissue (16). Clinical trial stud-
ies on comparison between E vitamin and placebo (17-
19) have not reported definite findings on this vitamin. 
However, these works have recommended that 400-1200 
mg tocopherol be used in view of various parameters in-
cluding pain at pressure, relaxation, and motion. Since 
administration of NSAIDs have significantly increased in 
recent years and these drugs, as with most drugs, lead to 
deleterious side effects if administered for long term (7, 
20), various studies on use of therapies that decrease con-
sumption of sedatives, cause satisfaction in patients, and 
decrease costs are important. Today, use of some vitamins 
and other supplements for pain relief and other symp-
toms of osteoarticular diseases including osteoarthritis is 
being challenged. The purpose of the present study is to 
determine the efficacy of B and E vitamins on pain relief in 
the patients with knee osteoarthritis and compare it with 
diclofenac as a type of NSAID.
2. PATIENTS AND METHODS
This double-blinded clinical trial was conducted in 
2013-2014 on 120 patients referring training Rheuma-
tology and Orthopedics Clinic of Shahrekord University 
of Medical Sciences with confirmed diagnosis of primary 
knee osteoarthritis. The inclusion criteria were the age of 
30 to 60 years, diagnosis of primary knee osteoarthritis 
by an orthopedics (per descriptions, clinical symptoms, 
physical examinations, radiologic and relevant diagnos-
tic criteria of this disease. The exclusion criteria were 
secondary knee osteoarthritis, primary infection or in-
flammatory disease in knee joint, arthritis due to crystal, 
intra-articular tumors, knee ligament instability, previous 
intra-articular fracture, knee joint surgery (arthroscopic 
or otherwise) in the past 12 months, intra-articular injec-
tion, visual analogue scale (VAS) score less than 3 for the 
knee under treatment at treatment initiation, concomi-
tant severe diseases such as metabolic diseases, history of 
some diseases like stroke, uncontrolled hypertension, gas-
tritis, infectious diseases, kidney failure, ulcer, and sensi-
tivity to vitamin B complex, vitamin E, and vitamin B, and 
other contraindications of vitamins B and E administra-
tion. In case of development of the complications due to 
the drugs, lack of regular consumption of the drug (vita-
min B complex and vitamin E), sensory impairment in the 
lower limbs, use of an additional sedative, lack of patient’s 
cooperation, and pregnancy, the patient was excluded 
from the study. After being enrolled and completing con-
sent form, the patients were randomly assigned to three 
groups of 40 each: one control group and two interven-
tion groups. All three groups were administered with oral 
diclofenac 50 mg twice a day. For intervention 1 group, 
intervention 2, and control groups, respectively vitamin 
B complex tablet, vitamin E tablet 100 mg, and diclofenac 
plus a placebo tablet was daily administered. The patients 
were examined three times (on the first day, day 14, and 
day 21) and the relevant questionnaire was completed for 
them. First section: Demographic variables including age, 
gender, occupation, education, marital status, and body 
mass index (BMI); second section: VAS questionnaire 
ticked by the patients using a 100-mm horizontal line 
in the three steps; and the third section: WOMAC stan-
dard questionnaire used for assessment of morning stiff-
ness and physical performance in the patients. WOMAC 
questionnaire has been studied in several studies and its 
validity and reliability have been confirmed (21-23). The 
questionnaire items have been codified as Likert scale 
(painless, mild pain, moderate pain, severe pain, very 
severe pain) and assessment is done in three sections: 1. 
Pain assessment (5 items); 2. Joint stiffness (2 items); and 
3. Physical function (17 items). The pain which is exam-
ined in the present study is assessed by the five first items 
of this questionnaire (pain section) and VAS at the end 
of the questionnaire. After gathering the data, we ana-
lyzed the data by SPSS 17 using descriptive statistics, chi 
square, analysis of variance (ANOVA), and repeated mea-
sures ANOVA.
3. RESULTS
Of 120 patients participating in this study. 12 (5 in di-
clofenac and vitamin E groups and 4 in vitamin B group) 
declined to continue participating and finally the data of 
108 patients were analyzed. In diclofenac group (n=37) 
57.1% (n=20) were female, 42.9% (n=15) were male, and 
the patients were 30 to 63 years old. In vitamin E group 
(n=35) 62.9% (n=22) were female, 37.1% (n=15) were 
male, and the patients were 30 to 60 years old. In vitamin 
B group (n=38) 55.3% (n=21) were female, 44.71% (n=17) 
were male, and the patients were 33 to 60 years old. Mean 
age was 46.40±8.7 years in diclofenac group, 47.54±8.97 
in vitamin E group, and 46.78±8.31 in vitamin B group. 
In addition, the mean BMI was 26.31±3.09 in diclofenac 
group, 26.40±1.97 in vitamin E group, and 27.51±3.76 in 
vitamin B group. Most patients in the diclofenac group, 
the vitamin E group, and the vitamin B group were respec-
tively public servant, housewife, and housewife (51.4%, 
34.3%, and 39.15%, respectively). Also, most patients in 
the diclofenac group (62.4%) were holders of associate de-
gree and higher and in the vitamin E and vitamin B groups 
(respectively 37.1% and 36.8%) were illiterate. Chi square 
indicated no statistically significant difference in age, gen-
der, and occupation among the groups (p>0.05) (Table 1). 
ANOVA indicated no statistically significant difference 
in BMI among the groups (p=0.17). By ANOVA, mean 
score of WOMAC (knee pain VAS, total pain severity, 
knee joint stiffness, and the past 48-hour function) was 
not significantly different prior to and after the first ex-
amination among the three groups (p>0.05). In addition, 
in the second examination only the past 48-hour function 
was lower in the vitamin E group than in the vitamin B 
and diclofenac groups and other variables of study (knee 
pain VAS, total pain severity, and knee joint stiffness) 
were reported lower in the vitamin B group than in the 
vitamin E and diclofenac groups (p>0.05). In the third ex-
amination, the mean score of all WOMAC sections was 
lower in the vitamin B group than in the vitamin E and 
diclofenac groups with no statistically significant differ-
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ence (p>0.05) (Table 2). By repeated measures ANOVA, 
decrease in knee pain VAS, total pain severity, knee joint 
stiffness, and the past 48-hour function changed signifi-
cantly from the first to the third examination (p=0.001). 
Except for knee joint stiffness with a similar decreasing 
trend in all three groups, other variables including knee 
pain VAS, total pain severity, knee joint stiffness, and the 
past 48-hour function changed differently in the three 
groups so that decrease in knee pain VAS and the past 48-
hour function was reported higher in the vitamin B group 
than in the diclofenac and vitamin E groups (p=0.008) and 
the decrease in total pain severity was reported higher in 
the vitamin B group than in the diclofenac and vitamin E 
groups (p=0.019).On satisfaction with treatment, by chi 
square test the patients in the vitamin B group reported 
a higher satisfaction than those in the diclofenac and vi-
tamin E groups so that 29 (76.3%) patients in the vitamin 
B group, 25 (71.4%) patients in the diclofenac group, and 
24 (68.6%) patients in the vitamin E group had a high and 
very high satisfaction, but generally the difference was not 
reported as statistically different (p=0.45).
4. DISCUSSION
Osteoarthritis is one of the most prevalent diseases 
which involves many joints in the body including knee 
joint. NSAIDs including diclofenac are considered as the 
first line drugs for this disease. Administration of these 
drugs has become restricted because of their complica-
tions and risks with upper gastrointestinal tract toxicity, 
edema, and renal failure as the most prevalent. The pres-
ent study was conducted to compare B and E vitamins 
with diclofenac in osteoarthritis treatment. In this study, 
the patients underwent treatment for three weeks (day 
1, day 14, and day 21). By the findings of this study, the 
treatment led to pain relief in all three (vitamin B, vitamin 
E, and diclofenac) groups according to WOMAC ques-
tionnaire and the symptoms recovered significantly in all 
three groups after the third examination (day 21).
Mean VAS of knee pain was 9.18 in the first examination 
and 3.78 in the third examination in the vitamin B group, 
9.51 in the first examination and 5.17 in the third exam-
ination in the vitamin E group, and 8.82 in the first exam-
ination and 4.74 in the third examination in the diclofenac 
group. Totally, the decrease in knee pain VAS was signifi-
cantly higher in the vitamin B group than in the vitamin E 
and diclofenac groups. Mean total pain severity was 35.73 
in the first examination and 14 in the third examination 
in the vitamin B group, 34.08 in the first examination and 
17.02 in the third examination in the vitamin E group, and 
33.34 in the first examination and 17.51 in the third ex-
amination in the diclofenac group. Totally, the decrease in 
total pain severity was significantly higher in the vitamin 
B group than in the vitamin E and diclofenac groups. In a 
similar study, Magana-Villa et al indicated that diclofenac 
combined with vitamin B groups had better analgesic ef-
fects in the interval under study and a better understand-
ing of pain relief by the patients compared with diclofenac 
alone. This study was some clinical support for improve-
ment of diclofenac analgesic effect after combination with 
vitamin B in osteoarthritis patients (24). Also, in Brug-
gemann et al study, promotion of analgesic effect of di-
clofenac by vitamin B complex was reported for recovery 
of low back pain (25). In Hector et al study, the analgesic 
effect of B complex was demonstrated and combined ad-
ministration of diclofenac and B complex was highlighted 
as a suitable, cheap approach to relieving the pain before 
and after surgery (26).
Various mechanisms have been recommended to ex-
plain how vitamin B complex affects pain relief and in-
flammation in laboratory experiments. For example, this 
vitamin could lead to enhanced effect and/or availability 
of norepinephrine and also increased activity of 5-HT 
that contributes to pain transmission as an inhibitory 
pain transmitter (27). In an in vitro study Reyes-Garcia 
reported analgesic and anti-inflammatory effects of B 
complex that were relevant to the mechanisms similar to 
opioids and mediated by releasing nitrite oxide (11,28). In 
Reyes-Garcia study the analgesic effect of B12 was higher 
than B6 and that of B6 was higher than B1 (28).
In a study in 2006-2007 the effects of vitamin E and 
glucosamine sulfate on pain relief were compared in the 
patients with knee osteoarthritis. After a six-month treat-
ment, both groups exhibited a pronounced recovery by 
3. RESULTS 
Of 120 patients participating in this study. 12 (5 in diclofenac and vitamin E 
groups and 4 in vitamin B group) declined to continue participating and finally the data 
of 108 patients were analyzed. In diclofenac group (n=37) 57.1% (n=20) were female, 
42.9% (n=15) were male, and the patients were 30 to 63 years old. In vitamin E group 
(n=35) 62.9% (n=22) were female, 37.1% (n=15) were male, and the patients were 30 
to 60 years old. In vitamin B group (n=38) 55.3% (n=21) were female, 44.71% (n=17) 
were male, and the patients were 33 to 60 years old. Mean age was 46.40±8.7 years in 
diclofenac group, 47.54±8.97 in vitamin E group, and 46.78±8.31 in vitamin B group.  
In addition, the mean BMI was 26.31±3.09 in diclofenac group, 26.40±1.97 in vitamin 
E group, and 27.51±3.76 in vitamin B group. Most patients in the diclofenac group, the 
vitamin E group, and the vitamin B group were respectively public servant, housewife, 
and housewife (51.4%, 34.3%, and 39.15%, respectively). Also, most patients in the 
diclofenac group (62.4%) were holders of associate degree and higher and in the 
vitamin E and vitamin B groups (respectively 37.1% and 36.8%) were illiterate. Chi 
square indicated no statistically significant difference in age, gender, and occupation 
among the groups (p>0.05) (Table 1). ANOVA indicated no statistically significant 
difference in BMI among the groups (p=0.17). 
Table 1. Frequency distribution for demographic ariables of the patients in three 
diclofenac, vitamin E, and vitamin B groups   
 P-
value  
Vitamin B 
(%) 
Vitamin E 
(%) 
Diclofenac 
(%) 
 
                       
 
0.78 
11 (28.9) 9 (25.7) 7 (20) 30-40 
Age (years) 13 (34.2) 11 (31.4)  16 (45.7) 40-50 
14 (36.8) 15 (42.9)  12 (34.3)  50-60 
0.79 21 (55.3) 22 (62.9)  20 (57.1)   Female Gender 17 (44.7) 13 (37.1)  15 (42.9)  Male 
0.36 
11 (28.9) 11 (31.4)  18 (51.4)  Civil servant 
Occupation 8 (21.1) 9 (25.7)  6 (17.1)  Non civil servant 
15 (39.5) 12 (34.3)  11 (31.4)  Housewife 
4 (10.5) 3 (8.6) 0  Jobless 
0.032 
14 (36.8)  13 (37.1) 5 (14.3)    Illiterate 
Education 
4 (10.5)  7 (20)  3 (8.6)  Under diploma 
8 (21.1) 2 (5.7) 5 (14.3)  Diploma 
12 (31.6)  13 (37.1)  22 (62.9)  Associate diploma 
0.36 2 (5.3) 0 2 (5.7)  Single Marital status 36 (49.7) 35 (100)  33 (94.7)  Married 
 
 
 
Table 1. Frequency distribution for demographic variables of the 
patients in three diclofenac, vitamin E, and vitamin B groups
By ANOVA, mean score of WOMAC (knee pain VAS, total pain severity, knee 
joint stiffness, and the past 48-hour function) was not significantly different prior to 
and after the first examination among the three groups (p>0.05). In addition, in the 
second examination only the past 48-hour function was lower in the vitamin E group 
than in the vitamin B and diclofenac groups and other variables of study (knee pain 
VAS, total pain severity, and knee joint stiffness) were reported lower in the vitamin B 
group than in the vitamin E and diclofenac groups (p>0.05). In the third examination, 
the mean score of all WOMAC sections was lower in the vitamin B group than in the 
vitamin E and diclofenac groups with no statistically significant difference (p>0.05) 
(Table 2). 
Table 2. Comparison of mean WOMAC questionnaire scales of the patients in three diclofenac, 
vitamin E, and vitamin B groups   
P-value 
 
Vitamin B Vitamin E Diclofenac                                  
Mean  SD  Mean  SD  Mean  SD  
0.83 
9.18  2.10 9.51  2.60 
9.12  2.67 
day visit st1 
VAS of right 
or left knee 
pain or both 
0.41 4.97  2.95 5.77  2.81 5.82  2.67 4th day visit 
0.17 3.78  2.87 5.17  2.96 4.74  3.82 day visit st21 
0.37 35.73  7.33 34.08  7.69 34.34  7.46 day visit 
st1 
Total pain 
severity in the 
past 48 hours 
0.53 17.84  9.7 18.97  9.74 20.51  11.05  
4th day visit 
0.33 14  9.99 17.02  10.31 17.51  12.64 day visit st21 
0.46 9.86  4.87 11.17  4.15 10.28  4.93 day visit 
st1 
Knee joint 
stiffness 0.06 
5.60  3.85 7.51  3.74 7.48  4.35 4th day visit 
0.07 4.94  3.76 6.82  3.96 6.94  4.8 day visit st21 
0.12 92.55  29.59 79.47  25.72 92  32.75 day visit 
st1 
Function in 
the past 48 
hours 
0.23 47.44  30.52 46.57  26.40 58  35.89 4th day visit 
0.25 37.86  30.06 46.05  27.66 50.45  39.07 day visit 
st21 
 
Table 2. Comparison of mean WOMAC questionnaire scales of 
the patients in three diclofenac, vitamin E, and vitamin B groups
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WOMAC scale and a considerable decrease in VAS in 
both standing and sitting positions with no significant dif-
ference. That study reported that oral vitamin E at 400 mg 
dose per day contributes potentially to decreasing symp-
toms in knee osteoarthritis patients with no serious side 
effects (29). In addition, Brand et al study in contrast to 
our study compared the effects of oral vitamin E and pla-
cebo on reducing symptoms of knee osteoarthritis. The 
two groups indicated no recovery by WOMAC and no 
significant decrease in knee pain, morning stiffness, and 
daily functioning by VAS, and no significant difference 
was observed between the two groups. The findings of 
this six-month study represented vitamin E as playing no 
role in recovery of knee osteoarthritis symptoms (30). No 
explanation has been yet offered for the mechanism of vi-
tamin E effect on osteoarthritis and this has remained un-
known. However, vitamin E effect seems to be related to 
alpha tocopherol activity against oxygen free radicals and 
lipids peroxidation. A study by Surapaneni et al compared 
serum levels of various compounds including vitamin E 
in the patients with and without osteoarthritis. Vitamin E 
level was lower in the patients than in the controls in that 
study arguing oxygen free radicals and oxidative reactions 
contributed to developing osteoarthritis (31). Also, the 
role of vitamin E in treating chronic polyarthritis symp-
toms was well demonstrated in Wittenborg et al study 
(32).
5. CONCLUSION
Since alternative therapies have been repeatedly stud-
ied in numerous works including those investigating the 
effect of vitamins B and E on osteoarthritis symptoms and 
in view of the present study findings, similar analgesic and 
anti-inflammatory effects of vitamins E and B, and their 
few and infrequent complications, use of both and/or oth-
er drugs with a different mechanism of effect is recom-
mended to enhance their effect on treating osteoarthritis 
symptoms.
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